Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models.

The emergence of antibiotic resistance in a wide variety of important pathogens of humans presents a worldwide threat to public health. This paper describes recent work on the use of mathematical models of the emergence and spread of resistance bacteria, on scales ranging from within the patient, in hospitals and within communities of people. Model development starts within the treated patient, and pharmacokinetic and pharmacodynamic principles are melded within a framework that mirrors the interaction between bacterial population growth, drug treatment and the immunological responses targeted at the pathogen. The model helps identify areas in which more precise information is needed, particularly in the context of how drugs influence pathogen birth and death rates (pharmacodynamics). The next area addressed is the spread of multiply drug-resistant bacteria in hospital settings. Models of the transmission dynamics of the pathogen provide a framework for assessing the relative merits of different forms of intervention, and provide criteria for control or eradication. The model is applied to the spread of vancomycin-resistant enterococci in an intensive care setting. This model framework is generalized to consider the spread of resistant organisms between hospitals. The model framework allows for heterogeneity in hospital size and highlights the importance of large hospitals in the maintenance of resistant organisms within a defined country. The spread of methicillin resistant Staphylococcus aureus (MRSA) in England and Wales provides a template for model construction and analysis. The final section addresses the emergence and spread of resistant organisms in communities of people and the dependence on the intensity of selection as measured by the volume or rate of drug use. Model output is fitted to data for Finland and Iceland and conclusions drawn concerning the key factors determining the rate of spread and decay once drug pressure is relaxed.

[1]  R. Albert,et al.  Hand-washing patterns in medical intensive-care units. , 1981, The New England journal of medicine.

[2]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[3]  William H. Press,et al.  Numerical Recipes: FORTRAN , 1988 .

[4]  K. Arheart,et al.  The role of handwashing in prevention of endemic intensive care unit infections. , 1990, Infection control and hospital epidemiology.

[5]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[6]  D. Livermore Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.

[7]  J. Sobel,et al.  Epidemiology of nosocomial acquisition of Candida lusitaniae , 1992, Journal of clinical microbiology.

[8]  B. Doebbeling,et al.  Comparative Efficacy of Alternative Hand-Washing Agents in Reducing Nosocomial Infections in Intensive Care Units , 1992 .

[9]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[10]  T. Frieden,et al.  Emergence of vancomycin-resistant enterococci in New York City , 1993, The Lancet.

[11]  E Massad,et al.  Modeling and simulating the evolution of resistance against antibiotics. , 1993, International journal of bio-medical computing.

[12]  G. Drusano,et al.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis , 1993, Antimicrobial Agents and Chemotherapy.

[13]  D. Nathwani,et al.  Penicillins. A current review of their clinical pharmacology and therapeutic use. , 1993 .

[14]  David R. Appleton,et al.  Modelling Biological Populations in Space and Time , 1993 .

[15]  Epidemic methicillin resistant Staphylococcus aureus in 1993. , 1994, Communicable disease report. CDR weekly.

[16]  R. Lenski,et al.  Genetic analysis of a plasmid-encoded, host genotype-specific enhancement of bacterial fitness , 1994, Journal of bacteriology.

[17]  A. Salyers,et al.  Bacterial Pathogenesis: A Molecular Approach , 1994 .

[18]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[19]  B. Cookson,et al.  Aspects of the epidemiology of MRSA in Europe. , 1995, Journal of chemotherapy.

[20]  S. Mehtar Infection control programmes--are they cost-effective? , 1995, The Journal of hospital infection.

[21]  L. Rice,et al.  Controlling Vancomycin-Resistant Enterococci , 1995, Infection Control & Hospital Epidemiology.

[22]  C. Benson,et al.  Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection , 1995 .

[23]  P Huovinen,et al.  Development of beta-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  D. Goldmann,et al.  Reducing the spread of antimicrobial-resistant microorganisms. Control of vancomycin-resistant enterococci. , 1995, Pediatric clinics of North America.

[25]  D. Morrison Vancomycin resistant enterococci in hospitals in the United Kingdom. , 1995, Communicable disease report. CDR weekly.

[26]  J. Morris,et al.  Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin: Establishment of Endemicity in a University Medical Center , 1995, Annals of Internal Medicine.

[27]  Jerome J. Schentag,et al.  In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.

[28]  G. Stefánsdóttir,et al.  Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study , 1996, BMJ.

[29]  J. Mcgowan,et al.  Reasons for the emergence of antibiotic resistance. , 1996, The American journal of the medical sciences.

[30]  J. Kalbfleisch,et al.  Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA , 1996 .

[31]  R. Weinstein,et al.  Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci , 1996, The Lancet.

[32]  E O Voit,et al.  A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro. , 1996, Bulletin of mathematical biology.

[33]  Ingemar Nåsell,et al.  The quasi-stationary distribution of the closed endemic sis model , 1996, Advances in Applied Probability.

[34]  K. K. Lai Control of Vancomycin-Resistant Enterococcus , 1997, Annals of Internal Medicine.

[35]  N. Shigesada,et al.  Biological Invasions: Theory and Practice , 1997 .

[36]  I. Bowler Strategies for the management of healthcare staff colonized with epidemic methicillin-resistant Staphylococcus aureus. , 1997, The Journal of hospital infection.

[37]  R. A. Cox,et al.  Strategies for the management of healthcare staff colonized with epidemic methicillin-resistant Staphylococcus aureus. , 1997, The Journal of hospital infection.

[38]  S. Sylvan,et al.  Carriage of multiresistant Streptococcus pneumoniae among children attending day-care centres in the Stockholm area. , 1997, Scandinavian journal of infectious diseases.

[39]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[40]  S Bonhoeffer,et al.  Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Valleron,et al.  Modeling the Spread of Resistant Nosocomial Pathogens in an Intensive-Care Unit , 1997, Infection Control & Hospital Epidemiology.

[42]  Sylvie Chevret,et al.  Modeling the spread of resistant nosocomial pathogens in an intensive-care unit. , 1997 .

[43]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[44]  B. Levin,et al.  Adaptation to the fitness costs of antibiotic resistance in Escherichia coli , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[45]  S. Tabaqchali Vancomycin-resistant Staphylococcus aureus: apocalypse now? , 1997, The Lancet.

[46]  M Kakehashi,et al.  The transmission dynamics of antibiotic–resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[47]  B. Levin,et al.  The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.

[48]  F. M. Stewart,et al.  The population genetics of antibiotic resistance. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  R. Lenski,et al.  The cost of antibiotic resistance--from the perspective of a bacterium. , 2007, Ciba Foundation symposium.

[50]  K. Bowker,et al.  Vancomycin-resistant Staphylococcus aureus , 1998, The Lancet.

[51]  D. Andersson,et al.  Virulence of antibiotic-resistant Salmonella typhimurium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  O. Cars,et al.  In Vitro Studies of Pharmacodynamic Properties of Vancomycin against Staphylococcus aureus andStaphylococcus epidermidis , 1998, Antimicrobial Agents and Chemotherapy.

[53]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[54]  A S Perelson,et al.  Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. , 1998, The Journal of infectious diseases.

[55]  M. Zervos,et al.  Treatment of Vancomycin-Resistant Enterococcus faeciumwith RP 59500 (Quinupristin-Dalfopristin) Administered by Intermittent or Continuous Infusion, Alone or in Combination with Doxycycline, in an In Vitro Pharmacodynamic Infection Model with Simulated Endocardial Vegetations , 1998, Antimicrobial Agents and Chemotherapy.

[56]  D. Austin,et al.  Vancomycin-resistant enterococci in intensive care hospital settings. , 1998, Memorias do Instituto Oswaldo Cruz.

[57]  R. Anderson,et al.  The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. , 1998, Journal of theoretical biology.

[58]  S. Blower,et al.  Predicting and preventing the emergence of antiviral drug resistance in HSV-2 , 1998, Nature Medicine.

[59]  R. Anderson,et al.  The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Anderson,et al.  Vancomycin-resistant enterococci in intensive-care hospital settings: Transmission dynamics, persistence, and the impact of infection control programs (nosocomial infectionsymathematical models) , 1999 .

[61]  R. Anderson,et al.  Transmission dynamics of epidemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in England and Wales. , 1999, The Journal of infectious diseases.

[62]  A. L.,et al.  Spatial Heterogeneity in Epidemic Models , 2022 .